ACET - Adicet Bio Inc

7.02
-0.270   -3.846%

Share volume: 111,260
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$7.29
-0.27
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 40%
Dept financing 22%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.17%
1 Month
-5.52%
3 Months
1,164.86%
6 Months
884.30%
1 Year
705.97%
2 Year
194.96%
Key data
Stock price
$7.02
P/E Ratio 
N/A
DAY RANGE
$6.67 - $7.13
EPS 
-$1.28
52 WEEK RANGE
$0.45 - $9.05
52 WEEK CHANGE
$702.19
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
153.256 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$76,709
AVERAGE 30 VOLUME 
$182,525
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Recent news